Cargando…

Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)

BACKGROUND: Community acquired pneumonia (CAP) is a major cause of morbidity, hospitalization, and mortality worldwide. Management of CAP for many patients requires rapid initiation of empirical antibiotic treatment, based on the spectrum of activity of available antimicrobial agents and evidence on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuzman, Ilija, Bezlepko, Alexandr, Kondova Topuzovska, Irena, Rókusz, László, Iudina, Liudmyla, Marschall, Hans-Peter, Petri, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105837/ https://www.ncbi.nlm.nih.gov/pubmed/24975809 http://dx.doi.org/10.1186/1471-2466-14-105

Ejemplares similares

Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI)
por: Chuchalin, Alexander, et al.
Publicado: (2013)

Clinical, Laboratory and Radiographic Features of Patients with Pneumonia and Parapneumonic Effusions
por: Petrusevska-Marinkovic, Sanja, et al.
Publicado: (2016)

Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
por: Tang, Hung-Jen, et al.
Publicado: (2020)

Clinical Presentation and Laboratory Characteristics in Acute and Recurrent Erysipelas
por: Brishkoska-Boshkovski, Vesna, et al.
Publicado: (2019)

Efficacy and safety of sequential IV/PO moxifloxacin for the treatment of severe community-acquired pneumonia
por: Lode, H, et al.
Publicado: (2002)

An ethnobotanical survey of plants used to manage HIV/AIDS opportunistic infections in Katima Mulilo, Caprivi region, Namibia
por: Chinsembu, Kazhila C, et al.
Publicado: (2010)

Comorbidities as Risk Factors for Acute and Recurrent Erysipelas
por: Brishkoska-Boshkovski, Vesna, et al.
Publicado: (2019)

A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)
por: Ferrara, Anna M
Publicado: (2007)

Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS
por: Rahmel, Tim, et al.
Publicado: (2017)

Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis
por: Zhao, Mingye, et al.
Publicado: (2022)

Mycoplasma pneumoniae in adult community-acquired pneumonia increases matrix metalloproteinase-9 serum level and induces its gene expression in peripheral blood mononuclear cells
por: Puljiz, Ivan, et al.
Publicado: (2012)

Moxifloxacin modulates inflammation during murine pneumonia
por: Beisswenger, Christoph, et al.
Publicado: (2014)

Serum metabolite profiles as potential biochemical markers in young adults with community-acquired pneumonia cured by moxifloxacin therapy
por: Zhou, Bo, et al.
Publicado: (2020)

Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses
por: Du, Xiwen, et al.
Publicado: (2021)

Characteristics of an Outpatient Cohort with HBeAg-Negative Chronic Hepatitis B
por: Dimzova, Marija, et al.
Publicado: (2019)

Chlamydia Pneumoniae and Helicobacter Pylori Serology – Importance in Patients with Coronary Heart Disease
por: Grdanoska, Tatjana, et al.
Publicado: (2012)

Update on the Cardiac Safety of Moxifloxacin
por: Haverkamp, Wilhelm, et al.
Publicado: (2012)

A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP)
por: Horcajada, Juan P, et al.
Publicado: (2019)

Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study
por: Ramirez, Julio, et al.
Publicado: (2021)

Noninvasive Biomarkers in Assessment of Liver Fibrosis in Patients with HBeAg Negative Chronic Hepatitis B
por: Dimzova, Marija, et al.
Publicado: (2018)

Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection
por: Lodise, Thomas P., et al.
Publicado: (2021)

2232. A Global Phase 3 Study of Delafloxacin (DLX) Compared with Moxifloxacin (MOX) in Patients with Community-acquired Bacterial Pneumonia (CABP)
por: Salata, Robert, et al.
Publicado: (2019)

Epileptic Seizure after Use of Moxifloxacin in Man with Legionella longbeachae Pneumonia
por: Wang, Jin-Yong, et al.
Publicado: (2020)

A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia
por: Tokimatsu, Issei, et al.
Publicado: (2017)

Moxifloxacin-warfarin interaction
por: Ji, Yan, et al.
Publicado: (2012)

684. Cardiac Safety in Adults with Community-Acquired Bacterial Pneumonia (CABP) Treated with Lefamulin (LEF) or Moxifloxacin (MOX): Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Darpo, Borje, et al.
Publicado: (2019)

699. Hepatobiliary Safety in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Lewis, James H, et al.
Publicado: (2019)

Moxifloxacin Safety: An Analysis of 14 Years of Clinical Data
por: Tulkens, Paul M., et al.
Publicado: (2012)

Safety and tolerability of moxifloxacin for the treatment of disseminated BCGitis in children
por: Alsuhaibani, Mohammed, et al.
Publicado: (2019)

The role of moxifloxacin in tuberculosis therapy
por: Gillespie, Stephen H.
Publicado: (2016)

Moxifloxacin Concentration and Proteomic Analysis of Aqueous Humor in Human Uveitis Associated with Oral Moxifloxacin Therapy
por: Hinkle, David M, et al.
Publicado: (2017)

Moxifloxacin and bilateral acute iris transillumination
por: Knape, Robert M, et al.
Publicado: (2013)

Recurrent episodes of hypoglycemia induced by moxifloxacin
por: Singal, Dinesh Kumar, et al.
Publicado: (2013)

Moxifloxacin Increases Heart Rate in Humans
por: Mason, Jay W., et al.
Publicado: (2017)

Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial
por: McCurdy, Sandra, et al.
Publicado: (2020)

Intravenous moxifloxacin in routine hospital treatment of respiratory tract infections in China: results of a multicenter, noninterventional study
por: Chen, Rongchang, et al.
Publicado: (2011)

Safety of intracameral application of moxifloxacin and dexamethasone (Vigadexa®) after phacoemulsification surgery
por: Galvis, Virgilio, et al.
Publicado: (2023)

Moxifloxacin-Induced Thrombocytopenia Mediated by Moxifloxacin-Dependent IgM and IgG Antiplatelet Antibodies: A Case Report
por: Moore, Joel, et al.
Publicado: (2020)

2386. Efficacy of Lefamulin (LEF) vs. Moxifloxacin (MOX) Against Common Pathogens in Adults With Community-Acquired Bacterial Pneumonia (CABP): Results From the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study
por: File, Thomas, et al.
Publicado: (2018)

Moxifloxacin in the treatment of skin and skin structure infections
por: Guay, David RP
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_a69c5b2uk5tfko7f3r3ogvm8vc